Viome Life Sciences, a biotechnology company, unveiled its CancerDetect test for oral & throat cancer, the first launch in a series of diagnostic tests in development.

This test detects biomarkers for early-stage oral and throat cancers based on technology that has received FDA Breakthrough Device Designation. CancerDetect is available to individuals at higher risk of developing these cancers, fulfilling an unmet need for advanced, earlier detection when it is most easy to treat. Viome’s launch of the CancerDetect indicates continued growth in saliva-based, early cancer detection testing with Viome’s advanced mRNA technology and AI-powered platform, the company says.  

CancerDetect brings improved accuracy to early cancer detection and prevention as an oral and throat cancer test that offers detection with 95% specificity and 90% sensitivity.

Oral and throat cancer is notoriously difficult to detect. Until now, it can often go undiagnosed until it has reached an advanced stage due to a lack of effective diagnostics tools, leading to low survival rates. Only 28% of patients receive an early diagnosis, and those receiving a late diagnosis face a prolonged battle with oral cancer, according to the National Library of Medicine.

Early detection directly increases the five-year survival rate for oral cancer patients, from 50% to 84%.  With CancerDetect, Viome has developed a solution aimed at detecting early-stage cancer, leading to more successful treatment outcomes when confirmed with a biopsy.

“Despite all the innovations across the health landscape, oral and throat cancer has remained life-threatening diseases with few options for early detection,” says Naveen Jain, Founder and CEO of Viome Life Sciences. “As an industry leader on a mission to identify and address the roots of chronic disease, we have been working for years to bring to market clinically-backed diagnostics solutions for cancer detection and other life-threatening and debilitating diseases. With the launch of CancerDetect for Oral and Throat Cancer, we have achieved this goal and plan to follow this in rapid succession with detection tools for additional life-threatening chronic diseases and cancers.”

CancerDetect marks the latest addition to Viome’s suite of clinically-backed Intelligence wellness tests, including the recently-launched Full Body Intelligence Test, an at-home microbiome test. Following the CancerDetect test for oral and throat cancer, Viome is focused on enhancing its tests for the spectrum of GI disorders, including cancers.